National Centre for Pharmacoeconomics, Old Stone Building (Top Floor), Trinity Centre for Health Sciences,St. James's Hospital, Dublin 8, Ireland
The NCPE considers scaubitril/valsartan (Entresto) a cost-effective treatment for adult patients with symptomatic chronic heart failure with reduced ejection fraction. Therefore reimbursement is recommended.
The NCPE does not recommend the reimbursement of lumacaftor + ivacaftor (Orkambi) for cystic fibrosis patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene at the submitted price. Patients on Managed Access Programme will continue on Orkambi